It's typically feast or famine when it comes to biotech stocks, but one big winner can more than make up for a bunch of losers. The secret is finding well-run companies delivering high-quality drugs before the market finds them.
Of course, that's easier said than done, and some biotech companies are already beyond their high-growth stage. Nevertheless, in that spirit, we'll use the aggregate intelligence of the 105,000-plus investors participating in Motley Fool CAPS to find biotech stocks that the community likes -- those with four- and five-star ratings. The community's approval could be a sign that further research is in order.
Here are five such stocks:
Company |
Market Cap |
% CAPS All-Star Bulls |
CAPS Rating
|
CAPS Research |
---|---|---|---|---|
Amgen |
$46.8 B |
94.3% |
**** |
|
Genentech |
$77.7 B |
96.3% |
**** |
|
Genzyme |
$17.4 B |
95.1% |
***** |
|
ViroPharma |
$697 M |
98.3% |
***** |
|
Gilead Sciences |
$49.0 B |
97.6% |
***** |
Source: Motley Fool CAPS, as of June 11, 2008.
Come and join us on CAPS to learn more about these and countless other interesting stock ideas. Sign up for free.